Notification of Licensing Authority for Drugs Controller (India)

## Policy Analysis Report: Notification Regarding Licensing Authority for Drugs Regulation **1. Executive Summary:** This report analyzes a notification (S.O. 5398(E)) issued by the Ministry of Health and Family Welfare, Department of Health and Family Welfare, Drugs Regulation Section, on November 21, 2022. The notification pertains to the appointment of a licensing authority for drugs regulation. Specifically, it appoints Dr. Venugopal Girdharilal Somani, holding the charge of Drugs Controller India, as the licensing authority until February 15, 2023, or until a permanent replacement is found, or until further orders. The key finding is the establishment of a temporary appointment to ensure continuity in the role of licensing authority. **2. Introduction:** This report provides an overview and analysis of the notification S.O. 5398(E) issued by the Ministry of Health and Family Welfare on November 21, 2022, concerning the appointment of a licensing authority within the Drugs Regulation Section. The analysis is based solely on the information provided in the policy text. **3. Policy Overview:** * This document can be considered a new policy because it's an official notification of a specific appointment of a licensing authority, not clearly an amendment to previous policy. * **Core Objective(s):** To ensure a continuous and authorized licensing authority for drugs regulation within the Central Drugs Standard Control Organisation (CDSCO) during a specific period. This ensures the uninterrupted enforcement of the Drugs Rules, 1945. **4. Background and Rationale:** The notification addresses the potential vacancy or gap in the position of licensing authority for drugs regulation. By temporarily appointing Dr. Somani, the Ministry ensures that the regulatory functions related to drug licensing continue without disruption. This is crucial for maintaining public health and safety. **5. Key Provisions / Changes:** * The notification appoints Dr. Venugopal Girdharilal Somani, holding the charge of Drugs Controller India, as the licensing authority. * This appointment is temporary, effective from November 21, 2022, and lasting until February 15, 2023, the arrival of a permanent replacement, or until further orders, whichever occurs first. * The appointment is made under the authority of clause (b) of rule 21 of the Drugs Rules, 1945. **6. Target Audience and Stakeholders:** The primary target audience and stakeholders include: * **Pharmaceutical Companies/Manufacturers:** Affected by the licensing decisions and regulatory oversight of the licensing authority. * **Central Drugs Standard Control Organisation (CDSCO):** The organization within which the appointed licensing authority operates. * **Ministry of Health and Family Welfare:** The governing body responsible for the CDSCO and drug regulation. * **Healthcare Professionals:** Those who depend on the supply of regulated medicines and drugs. * **Patients:** The ultimate beneficiaries of effective drug regulation. **7. Implementation Aspects (Inferred):** * **Responsible agency:** The Central Drugs Standard Control Organisation (CDSCO) is responsible for implementing the provisions of this notification, with Dr. Somani acting as the responsible authority. * **Timeline:** The appointment is time-bound, lasting until February 15, 2023, or until a successor is appointed, whichever is earlier. * **Procedures:** The notification triggers the transfer of responsibilities and authority to Dr. Somani for all licensing decisions related to drug regulation within the CDSCO. Existing processes under the Drugs Rules, 1945, remain in effect, but with Dr. Somani as the designated decision-maker. **8. Expected Outcomes / Impact of Changes:** The intended outcome is to ensure continuity in the regulation of drugs and pharmaceuticals in India. This temporary appointment prevents any disruption in the licensing process, ensuring that new drugs can be approved and existing drugs remain under proper regulatory control. The impact is to maintain the stability and effectiveness of the drug regulatory system. **9. Conclusion:** The notification S.O. 5398(E) represents a crucial administrative measure to maintain the integrity and efficiency of the drug regulation process in India. By temporarily appointing Dr. Venugopal Girdharilal Somani as the licensing authority, the Ministry of Health and Family Welfare has addressed a potential gap in leadership and ensured the continued oversight of the pharmaceutical industry. This appointment is significant for maintaining public health and fostering confidence in the regulatory system.

Key Entities Referenced